A randomized double-blind multi-dose placebo-controlled study to evaluate the efficacy safety and tolerability of GSK2330672 administration for the treatment of pruritus in patients with primary biliary cholangitis (GLIMMER: GSK triaL of IBAT inhibition with Multi-Dose Measurement for Evaluation of Response)
R
Raj Vuppalanchi, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Not Recruiting
100 years or below
All
Phase
N/A
1 Location
Brief description of study
The purpose of this study is to evaluate the efficacy, safety, and tolerability if a range of doses of GSK2330672 for the treatment of adults with moderate to severe pruritus associated with primary biliary cholangitis (PBC).
Detailed description of study
The purpose of this study is to evaluate the efficacy, safety, and tolerability if a range of doses of GSK2330672 for the treatment of adults with moderate to severe pruritus associated with primary biliary cholangitis (PBC).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: pruritus
-
Age: 100 years or below
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 1705641598
